Goto A, Niki T, Terado Y, Fukushima J, Fukayama M
Department of Human Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Histopathology. 2004 Oct;45(4):384-92. doi: 10.1111/j.1365-2559.2004.01967.x.
To determine the prevalence of CD99 expression in pancreatic endocrine tumours (PETs). We evaluated CD99 expression and analysed Ki67 labelling by immunohistochemistry in PETs.
Thirty-eight PETs from 33 patients were analysed. CD99 immunoreactivity was consistently observed in normal islets of the pancreas, regardless of the cell type. Tumours comprising more than 30% CD99+ cells were defined as positively immunoreactive for CD99. CD99 expression was observed in 20 of the 38 PETs examined, but not in any of the pancreatic tumours of other histological subtypes (10 ductal adenocarcinomas, five intraductal papillary-mucinous tumours, and two acinar cell tumours). Loss of CD99 expression was related to markers of worse prognosis for PET, including gross local invasion, metastasis to the lymph nodes or other organs, lymphatic or blood vessel invasion, and neuroendocrine carcinoma (NEC). Thus, CD99 expression may have an efficiency comparable to that of high Ki67 labelling index (5% or more) for prognostication.
CD99 expression was observed frequently and exclusively in PETs, and loss of CD99 expression in PETs was found to be associated with ominous prognostic indicators.
确定CD99在胰腺内分泌肿瘤（PETs）中的表达情况。我们通过免疫组织化学评估了PETs中CD99的表达并分析了Ki67标记情况。
分析了来自33例患者的38个PETs。无论细胞类型如何，在胰腺正常胰岛中均持续观察到CD99免疫反应性。肿瘤中CD99阳性细胞超过30%被定义为CD99免疫反应阳性。在所检查的38个PETs中，有20个观察到CD99表达，但在其他组织学亚型的胰腺肿瘤（10例导管腺癌、5例导管内乳头状黏液性肿瘤和2例腺泡细胞肿瘤）中均未观察到。CD99表达缺失与PET预后较差的标志物相关，包括大体局部侵犯、淋巴结或其他器官转移、淋巴管或血管侵犯以及神经内分泌癌（NEC）。因此，CD99表达对于预后评估的效能可能与高Ki67标记指数（5%或更高）相当。
CD99表达在PETs中频繁且仅在PETs中观察到，并且发现PETs中CD99表达缺失与不良预后指标相关。
